Question 1

What is Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL” used for?

Accepted Answer

This medication is an anticancer agent, prescribed for breast cancer. It prevents the growth and spread of cancer cells in the body.

Question 2

What pharmaceutical form is Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL” available in?

Accepted Answer

Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL”: 注射劑

Question 3

What are the side effects of Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL”?

Accepted Answer

Most Common
-


Decrease in white blood cells, anemia, weakness, fatigue, hair loss, nerve disease, nausea, and constipation.
Central Nervous system
-


Headache.
General
-


Weakness, fatigue and fever.
Gastrointestinal
-


Diarrhea and vomiting.
Musculoskeletal
-

Joint/muscle pain, back pain, bone pain and pain in extremity.
Metabolic
-


Loss of appetite and decreased weight.
Respiratory
-


Cough and difficulty in breathing.
Genitourinary
-

Urinary tract infection.

Question 4

Can Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL” be used during pregnancy?

Accepted Answer

(
AHT
)
For the active ingredient
eribulin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Question 5

What precautions should be taken with Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL”?

Accepted Answer

• Caution should be exercised in patients with history of liver, kidney, heart problems, any allergy, who are taking other medications, during pregnancy and breastfeeding.
•  It may cause dizziness, do not drive a car or operate machinery while taking this medication.
•  It may cause burning, numbness, or tingling in the hands or feet; if it is so consult with your doctor.
•  Avoid contact with people who have infections.
•  Avoid live vaccination during the treatment period.
•  It may reduce pl

Question 6

Who manufactures Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL”?

Accepted Answer

DR. REDDY’S LABORATORIES LTD., FTO-VII (TW)

Question 7

What ATC class does Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL” belong to?

Accepted Answer

Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL”: ATC L01XX41. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Eribulin Mesylate Injection 1 mg /2 mL (0.5 mg/mL) “DRL”

User Reviews